InsiderPulseNo transactions found.
No financial data available for AVLN.
Company may not file with SEC or CIK is unresolved.
Avalyn Pharma prices $300M IPO at $18 per share
Avalyn Announces Pricing of Upsized Initial Public Offering
Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury
U.S. IPO Weekly Recap: Nuclear Tech, Critical Materials, And More In A 4-IPO Week
U.S. IPO Weekly Recap: Pipeline Swells With Sizable IPO Filings As Metals Royalty Direct Lists
Inhaled drug developer Avalyn files for U.S. IPO
Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors